Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer Schering Pharmaceuticals has pledged a E1.5 million grant to develop hemophilia treatment centers throughout China. Over the next five years, Bayer's support will fund a variety of necessities, including equipment and supplies, patient programs, educational materials, medical training and nursing support.
Subscribe to our email newsletter
The Bayer China Hemophilia Treatment Center Development Project is a partnership between Bayer Schering Pharmaceuticals and the Chinese Society of Hematology to improve hemophilia care throughout the country.
China currently has six hemophilia treatment centers that are part of the Hemophilia Treatment Center Collaborative Network of China (HTCCNC). These centers will be further developed and strengthened as part of this initiative, the company said.
Michael Mathews, general manager, hematology, Bayer HealthCare Pharmaceuticals, said: “Our passion for improving the lives of people around the world motivated us to step forward with this major funding pledge. But more importantly, the results will help the quality of care to step ahead, giving Chinese people with hemophilia better opportunities to live the lives they choose. We also consider it a privilege and an honor to be supporting the Chinese hemophilia community in this effort.”